Arginine-substituted Arg²MP-C derivative achieves near complete wound closure in murine polymicrobial infections.
Background
Polymicrobial infections significantly compromise wound healing and limit therapeutic efficacy, often leading to poor outcomes. The synergistic interactions between multiple bacterial species, such as Escherichia coli and Staphylococcus aureus, exacerbate these challenges, making treatment notoriously difficult with conventional antibiotics due to rising antimicrobial resistance (AMR). There is a critical need for novel antimicrobial strategies that can effectively target diverse pathogens and promote tissue repair, moving beyond single-target approaches. Antimicrobial peptides (AMPs) offer a promising alternative due to their broad-spectrum activity and unique mechanisms of action.
Study Design
Researchers designed and synthesized arginine-substituted derivatives of the antimicrobial peptide Mastoparan-C (MP-C). They evaluated the in vitro antibacterial activity of these derivatives, specifically Arg²MP-C and Arg4.11.12MP-C, against Escherichia coli and Staphylococcus aureus. Mechanistic studies investigated membrane disruption and genomic DNA binding. For in vivo efficacy, a murine polymicrobial wound model was established. Mice were treated with Arg²MP-C, and primary endpoints included wound closure rates, bacterial load reduction, and assessment of tissue regeneration over a 10-day period.
Results
Among the synthesized derivatives, Arg²MP-C and Arg4.11.12MP-C demonstrated potent, broad-spectrum activity against both Escherichia coli and Staphylococcus aureus in vitro. This enhanced antibacterial activity correlated with increased positive charge and optimized hydrophobicity. Mechanistically, both peptides employed a dual-target strategy, effectively disrupting bacterial membranes and binding genomic DNA. > Arg²MP-C acted most rapidly against the E. coli envelope, while Arg4.11.12MP-C caused the strongest membrane damage to S. aureus. In the murine polymicrobial wound model, Arg²MP-C treatment nearly achieved complete wound closure by day 10. This treatment significantly reduced bacterial loads and actively promoted tissue regeneration, highlighting its multi-mechanistic action and potential as a therapeutic agent.
Why It Matters
This study offers a compelling strategy for developing next-generation antimicrobials to combat challenging polymicrobial wound infections, particularly in the face of rising antimicrobial resistance. Arginine engineering of natural peptides like Mastoparan-C provides a pathway to create agents with enhanced potency and dual-mechanistic action, targeting both bacterial membranes and DNA, which is crucial for overcoming resistance. The impressive in vivo efficacy of Arg²MP-C in a murine model, showing near complete wound closure and bacterial reduction, suggests a promising candidate for future clinical translation. This approach could lead to novel topical treatments that not only clear infection but also actively support tissue regeneration, potentially revolutionizing wound care protocols.